<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1051">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04431453</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-540-5823</org_study_id>
    <secondary_id>2020-001803-17</secondary_id>
    <nct_id>NCT04431453</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to &lt; 18 Years of Age With Coronavirus Disease 2019 (COVID-19)</brief_title>
  <acronym>CARAVAN</acronym>
  <official_title>A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to &lt; 18 Years of Age With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability, and
      pharmacokinetics (PK) of remdesivir (RDV) in participants with laboratory-confirmed
      coronavirus disease 2019 (COVID-19) aged 0 days to &lt; 18 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric participants will be enrolled as follows:

      Pediatric participants ≥ 28 days to &lt; 18 years old:

        -  Cohort 1: ≥ 12 years to &lt; 18 years and weight ≥ 40 kg

        -  Cohort 2: ≥ 28 days to &lt; 18 years and weight ≥ 20 kg to &lt; 40 kg

        -  Cohort 3: ≥ 28 days to &lt; 18 years and weight ≥ 12 kg to &lt; 20 kg

        -  Cohort 4: ≥ 28 days to &lt; 18 years and weight ≥ 3 kg to &lt; 12 kg

      Term neonatal participants 0 days to &lt; 28 days old:

        -  Cohort 5: ≥ 14 days to &lt; 28 days of age, gestational age &gt; 37 weeks and weight at
           screening ≥ 2.5 kg

        -  Cohort 6: 0 days to &lt; 14 days of age, gestational age &gt; 37 weeks and birth weight ≥ 2.5
           kg

      Preterm neonates and infants 0 days to &lt; 56 days old:

        -  Cohort 7: 0 days to &lt; 56 days of age, gestational age ≤ 37 weeks and birth weight ≥ 1.5
           kg
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 21, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Experiencing any Treatment-Emergent Adverse Events</measure>
    <time_frame>First dose date up to Day 30 Follow-up Assessment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities</measure>
    <time_frame>First dose date up to Day 30 Follow-up Assessment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentrations of Remdesivir (RDV) and Metabolites</measure>
    <time_frame>Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours</time_frame>
    <description>Plasma concentrations will be drawn as follows: (1) for cohorts 1-4 on Day 2, and Day 3, Day 5 is optional; (2) for cohorts 5-7 on Day 2 or Day 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Oxygenation Use</measure>
    <time_frame>Baseline, up to Day 30 Follow-up Assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Use of Mechanical Ventilation or Extracorporeal Membrane Oxygenation (ECMO)</measure>
    <time_frame>Baseline, up to Day 30 Follow-up Assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement on a 7-point Ordinal Scale</measure>
    <time_frame>First dose date up to 10 days</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at a given day. Each day, the worst score from the previous day will be recorded. The scale is as follows: 1.) Death 2.) Hospitalized, on invasive mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) 3.) Hospitalized, on non-invasive ventilation or high flow oxygen devices 4.) Hospitalized, requiring low flow supplemental oxygen 5.) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (coronavirus (COVID-19) related or otherwise) 6.) Hospitalized, not requiring supplemental oxygen - no longer required ongoing medical care (other than per protocol Remdesivir administration) 7.) Not hospitalized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) to Discharge From Hospital</measure>
    <time_frame>First dose date up to Day 30 Follow-up Assessment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days to First Confirmed Negative Polymerase Chain Reaction (PCR) Result</measure>
    <time_frame>First dose date up to 10 days</time_frame>
    <description>Confirmed negative PCR is defined by 2 consecutive negative PCR results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load</measure>
    <time_frame>Baseline, up to 10 days or up to the first confirmed negative PCR results (whichever comes first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin Concentrations in &lt; 14-day-old Participants</measure>
    <time_frame>First dose date up to 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Improvement Based on Scoring Using the Pediatric Early Warning Score (PEWS) Improvement Scale</measure>
    <time_frame>First dose date up to 10 days</time_frame>
    <description>The PEWS is measured by 3 components, including 1.) behavior, 2.) perfusion assessed by capillary refill and heart rate, and 3.) respiratory status assessed by respiratory rate, effort, and oxygen requirement. The score ranges between zero to 9 point, with 9 point representing the highest severity level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Sulfobutylether β-cyclodextrin Sodium (SBECD)</measure>
    <time_frame>Day 2: end of infusion and 4 hours post end of infusion, Day 3: pre-infusion and 2 hours post end of infusion, and Day 5: middle of infusion and 6 hours post end of infusion; infusion duration: 30 minutes to 2 hours</time_frame>
    <description>Plasma concentrations will be drawn as follows: (1) for cohorts 1-4 on Day 2, and Day 3, Day 5 is optional; (2) for cohorts 5-7 on Day 2 or Day 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Concomitant Use of Medications other than RDV for Treatment of Coronavirus Disease 2019 (COVID-19)</measure>
    <time_frame>First dose date up to Day 30 Follow-up Assessment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Remdesivir (RDV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive RDV up to 10 days. The RDV dose administered in each cohort is as follows:
Cohort 1: intravenous (IV) RDV 200 mg on Day 1 followed by IV RDV 100 mg daily
Cohorts 2-5: IV RDV 5 mg/kg on Day 1 followed by IV RDV 2.5 mg/kg daily
Cohorts 6-7: IV RDV at a dose to be determined based on RDV exposure data from Cohort 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Administered as an intravenous infusion</description>
    <arm_group_label>Remdesivir (RDV)</arm_group_label>
    <other_name>GS-5734™</other_name>
    <other_name>Veklury®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Aged &lt; 18 years of age who meet one of the following weight criteria (where permitted
             according to local law and approved nationally and by relevant institutional review
             board (IRB) or independent ethics committee (IEC)).

               -  a) Cohort 1: ≥ 12 years to &lt; 18 years of age and weight at screening ≥ 40 kg

               -  b) Cohorts 2-4: ≥ 28 days to &lt; 18 years of age and weight at screening ≥ 3 kg and
                  &lt; 40 kg

               -  c) Cohort 5: ≥ 14 days to &lt; 28 days of age, gestational age &gt; 37 weeks and weight
                  at screening ≥ 2.5 kg

               -  d) Cohort 6: 0 days to &lt; 14 days of age, gestational age &gt; 37 weeks and birth
                  weight of ≥ 2.5 kg

               -  e) Cohort 7: 0 days to &lt; 56 days of age, gestational age ≤ 37 weeks and birth
                  weight of ≥ 1.5 kg

          -  Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection confirmed by
             polymerase chain reaction (PCR)

          -  Hospitalized and requiring medical care for coronavirus disease 2019 (COVID-19)

        Key Exclusion Criteria:

          -  Concurrent treatment with other agents with actual or possible direct antiviral
             activity against SARS-CoV-2 &lt; 24 hours prior to study drug dosing

          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 5 X upper limit
             of normal (ULN)

          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m^2 using Schwartz formula
             for individuals ≥ 1 year of age

          -  Creatinine above protocol specified thresholds for &lt; 1 year of age

          -  Positive pregnancy test at Screening only for female of child bearing potential. Note:
             If female participants who become pregnant during the study or are discovered to be
             pregnant after receiving at least one dose may continue study drug, after discussion
             with the investigator

        Note: Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan University of California, Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital (Inpatient Visits)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tulane University School of Medicine</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Medical Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYC Health + Hospitals/Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health-Cohen Children's Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center-Levine Children's Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital/Lehigh Valley Health Network (LVH/LVHN)</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <zip>B95SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

